Krystal Biotech christens new manufacturing facility for KB103

|About: Krystal Biotech, Inc. (KRYS)|By:, SA News Editor

Krystal Biotech (KRYS +0.2%) has officially opened its new 4,500 sq. ft. cGMP manufacturing facility for lead candidate KB103, an off-the-shelf topical gene therapy for an inherited skin disorder called dystrophic epidermolysis bullosa.

Topline data from a Phase 2 study, GEM-1, should be available mid-year.

Subscribe for full text news in your inbox